150 related articles for article (PubMed ID: 22971003)
1. Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia.
Jamieson K; Odenike O
Expert Opin Pharmacother; 2012 Oct; 13(15):2171-87. PubMed ID: 22971003
[TBL] [Abstract][Full Text] [Related]
2. Novel strategies for relapsed and refractory acute myeloid leukemia.
Mato AR; Morgans A; Luger SM
Curr Opin Hematol; 2008 Mar; 15(2):108-14. PubMed ID: 18300756
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.
Short NJ; Ravandi F
Expert Rev Hematol; 2016 Jun; 9(6):529-34. PubMed ID: 27158854
[TBL] [Abstract][Full Text] [Related]
4. Vosaroxin : a novel antineoplastic quinolone.
Abbas JA; Stuart RK
Expert Opin Investig Drugs; 2012 Aug; 21(8):1223-33. PubMed ID: 22724917
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia.
Ferrara F; Palmieri S; Mele G
Haematologica; 2004 Aug; 89(8):998-1008. PubMed ID: 15339685
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia.
Watt TC; Cooper T
Pediatr Blood Cancer; 2012 Oct; 59(4):756-7. PubMed ID: 22052552
[TBL] [Abstract][Full Text] [Related]
7. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
8. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Kornblau SM; Gandhi V; Andreeff HM; Beran M; Kantarjian HM; Koller CA; O'Brien S; Plunkett W; Estey E
Leukemia; 1996 Oct; 10(10):1563-9. PubMed ID: 8847890
[TBL] [Abstract][Full Text] [Related]
9. Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.
Hotinski AK; Lewis ID; Ross DM
Expert Opin Pharmacother; 2015 Jun; 16(9):1395-402. PubMed ID: 25958926
[TBL] [Abstract][Full Text] [Related]
10. Treatment for relapsed acute myeloid leukemia: what is new?
Ofran Y; Rowe JM
Curr Opin Hematol; 2012 Mar; 19(2):89-94. PubMed ID: 22227525
[TBL] [Abstract][Full Text] [Related]
11. Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia.
DiNardo CD; Cortes JE
Expert Opin Investig Drugs; 2014 Feb; 23(2):265-72. PubMed ID: 24313331
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia.
Kantarjian HM; Beran M; O'Brien S; Robertson L; Siddik Z; Yoshida M; Yang LY; Rios MB; Keating MJ; Meyer M
Leukemia; 1996 Mar; 10(3):396-401. PubMed ID: 8642853
[TBL] [Abstract][Full Text] [Related]
13. The role of decitabine for the treatment of acute myeloid leukemia.
Ganetsky A
Ann Pharmacother; 2012 Nov; 46(11):1511-7. PubMed ID: 23115225
[TBL] [Abstract][Full Text] [Related]
14. The thorny issue of relapsed acute myeloid leukemia.
Kubal T; Lancet JE
Curr Opin Hematol; 2013 Mar; 20(2):100-6. PubMed ID: 23385612
[TBL] [Abstract][Full Text] [Related]
15. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
16. Progress in the problem of relapsed or refractory acute myeloid leukemia.
Mims AS; Blum W
Curr Opin Hematol; 2019 Mar; 26(2):88-95. PubMed ID: 30640734
[TBL] [Abstract][Full Text] [Related]
17. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes.
Prebet T; Vey N
Expert Opin Investig Drugs; 2011 Feb; 20(2):287-95. PubMed ID: 21192773
[TBL] [Abstract][Full Text] [Related]
18. Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?
Freeman C; Keane N; Swords R; Giles F
Expert Opin Pharmacother; 2013 Jul; 14(10):1417-27. PubMed ID: 23688047
[TBL] [Abstract][Full Text] [Related]
19. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
20. Laromustine (cloretazine).
Vey N; Giles F
Expert Opin Pharmacother; 2010 Mar; 11(4):657-67. PubMed ID: 20163276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
